The prevalence and burden of systemic lupus erythematosus in a medicare population: retrospective analysis of medicare claims

BACKGROUND: Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder which can affect multiple organs of the body, requiring ongoing disease management and healthcare resource utilization. The economic impact of SLE has not been evaluated in a Medicare population to date. This study was c...

Descripción completa

Detalles Bibliográficos
Autores principales: Garris, Cindy, Shah, Manan, Farrelly, Eileen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445996/
https://www.ncbi.nlm.nih.gov/pubmed/26019689
http://dx.doi.org/10.1186/s12962-015-0034-z
_version_ 1782373356341821440
author Garris, Cindy
Shah, Manan
Farrelly, Eileen
author_facet Garris, Cindy
Shah, Manan
Farrelly, Eileen
author_sort Garris, Cindy
collection PubMed
description BACKGROUND: Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder which can affect multiple organs of the body, requiring ongoing disease management and healthcare resource utilization. The economic impact of SLE has not been evaluated in a Medicare population to date. This study was conducted to assess the prevalence of SLE and its burden in terms of healthcare resource utilization and costs in a US Medicare population. METHODS: This was a retrospective observational study using Medicare medical claims data (5% random sample) for the period spanning 2003 to 2007. SLE patients were identified by having ≥2 medical claims with a primary or secondary diagnosis of ICD-9 code 710.0X. The earliest quarter of SLE diagnosis was defined as the index quarter. Prevalence of SLE, the proportion of SLE cases on disability benefits, and the contribution of SLE to new disability cases were evaluated. Healthcare resource utilization and direct medical costs (2008 US dollars) over 12 months were compared between a cohort of patients with SLE and a cohort without SLE matched on key demographics. Differences in outcomes between cohorts were assessed using McNemar’s test for dichotomous variables and paired t-tests for continuous variables. RESULTS: A total of 13,348 patients with SLE were identified. The prevalence of SLE was approximately 3 per 1000 Medicare beneficiaries. After matching, the sample consisted of 6,707 SLE and 13,414 non-SLE patients. On average, the SLE cohort compared with the non-SLE cohort had 2.4 times more physician visits, 2.7 times more hospitalizations, 2.2 times more outpatient visits, and 2.1 times more emergency room visits. A medical cost surplus of approximately $10,229 per patient per year in the SLE cohort relative to the non-SLE cohort was driven largely by inpatient hospitalization costs (p < 0.001). CONCLUSIONS: SLE prevalence was 3 per 1,000 Medicare patients. Patients with SLE consumed significantly more health care resources with significantly greater costs compared with those without SLE. Added costs were largely attributable to inpatient hospitalizations. The Medicare population is an important target for efforts to improve SLE disease management and reduce costs.
format Online
Article
Text
id pubmed-4445996
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44459962015-05-28 The prevalence and burden of systemic lupus erythematosus in a medicare population: retrospective analysis of medicare claims Garris, Cindy Shah, Manan Farrelly, Eileen Cost Eff Resour Alloc Research BACKGROUND: Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder which can affect multiple organs of the body, requiring ongoing disease management and healthcare resource utilization. The economic impact of SLE has not been evaluated in a Medicare population to date. This study was conducted to assess the prevalence of SLE and its burden in terms of healthcare resource utilization and costs in a US Medicare population. METHODS: This was a retrospective observational study using Medicare medical claims data (5% random sample) for the period spanning 2003 to 2007. SLE patients were identified by having ≥2 medical claims with a primary or secondary diagnosis of ICD-9 code 710.0X. The earliest quarter of SLE diagnosis was defined as the index quarter. Prevalence of SLE, the proportion of SLE cases on disability benefits, and the contribution of SLE to new disability cases were evaluated. Healthcare resource utilization and direct medical costs (2008 US dollars) over 12 months were compared between a cohort of patients with SLE and a cohort without SLE matched on key demographics. Differences in outcomes between cohorts were assessed using McNemar’s test for dichotomous variables and paired t-tests for continuous variables. RESULTS: A total of 13,348 patients with SLE were identified. The prevalence of SLE was approximately 3 per 1000 Medicare beneficiaries. After matching, the sample consisted of 6,707 SLE and 13,414 non-SLE patients. On average, the SLE cohort compared with the non-SLE cohort had 2.4 times more physician visits, 2.7 times more hospitalizations, 2.2 times more outpatient visits, and 2.1 times more emergency room visits. A medical cost surplus of approximately $10,229 per patient per year in the SLE cohort relative to the non-SLE cohort was driven largely by inpatient hospitalization costs (p < 0.001). CONCLUSIONS: SLE prevalence was 3 per 1,000 Medicare patients. Patients with SLE consumed significantly more health care resources with significantly greater costs compared with those without SLE. Added costs were largely attributable to inpatient hospitalizations. The Medicare population is an important target for efforts to improve SLE disease management and reduce costs. BioMed Central 2015-05-06 /pmc/articles/PMC4445996/ /pubmed/26019689 http://dx.doi.org/10.1186/s12962-015-0034-z Text en © Garris et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Garris, Cindy
Shah, Manan
Farrelly, Eileen
The prevalence and burden of systemic lupus erythematosus in a medicare population: retrospective analysis of medicare claims
title The prevalence and burden of systemic lupus erythematosus in a medicare population: retrospective analysis of medicare claims
title_full The prevalence and burden of systemic lupus erythematosus in a medicare population: retrospective analysis of medicare claims
title_fullStr The prevalence and burden of systemic lupus erythematosus in a medicare population: retrospective analysis of medicare claims
title_full_unstemmed The prevalence and burden of systemic lupus erythematosus in a medicare population: retrospective analysis of medicare claims
title_short The prevalence and burden of systemic lupus erythematosus in a medicare population: retrospective analysis of medicare claims
title_sort prevalence and burden of systemic lupus erythematosus in a medicare population: retrospective analysis of medicare claims
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445996/
https://www.ncbi.nlm.nih.gov/pubmed/26019689
http://dx.doi.org/10.1186/s12962-015-0034-z
work_keys_str_mv AT garriscindy theprevalenceandburdenofsystemiclupuserythematosusinamedicarepopulationretrospectiveanalysisofmedicareclaims
AT shahmanan theprevalenceandburdenofsystemiclupuserythematosusinamedicarepopulationretrospectiveanalysisofmedicareclaims
AT farrellyeileen theprevalenceandburdenofsystemiclupuserythematosusinamedicarepopulationretrospectiveanalysisofmedicareclaims
AT garriscindy prevalenceandburdenofsystemiclupuserythematosusinamedicarepopulationretrospectiveanalysisofmedicareclaims
AT shahmanan prevalenceandburdenofsystemiclupuserythematosusinamedicarepopulationretrospectiveanalysisofmedicareclaims
AT farrellyeileen prevalenceandburdenofsystemiclupuserythematosusinamedicarepopulationretrospectiveanalysisofmedicareclaims